|Day Low/High||51.57 / 52.83|
|52 Wk Low/High||46.52 / 135.43|
Positive data in bone disease in pediatric XLH patients under 5 years old and in TIO patients
Study did not meet its primary endpoint
Burosumab US BLA submission planned for August 2017
BLA filing for Burosumab planned with current clinical data package in 2H 2017
Huge profits could be on the doorstep for these hot breakout setups.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc.
Additional Phase 3 data on burosumab shows increased healing of fractures in adult XLH
Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ultragenyx Pharmaceutical Inc , where a total volume of 4,232 contracts has been traded thus far today, a contract volume which is representative of approximately 423,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64% of RARE's average daily trading volume over the past month, of 661,320 shares.
Sustained reduction in bone disease and improvement in growth through 64 weeks of treatment and sustained effect on bone mineral metabolites in patients under 5 years old
Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
Overall seizures not significantly reduced; decrease in absence seizures observed
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.